139 related articles for article (PubMed ID: 16253538)
1. Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost.
Caramaschi P; Biasi D; Canestrini S; Martinelli N; Perbellini L; Carletto A; Pieropan S; Volpe A; Bambara LM
Joint Bone Spine; 2006 Jan; 73(1):57-61. PubMed ID: 16253538
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
3. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
4. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
[TBL] [Abstract][Full Text] [Related]
5. Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.
Caramaschi P; Biasi D; Ferrari M; Volpe A; Martinelli N; Carletto A; Dal Forno P; Bambara LM
Rheumatol Int; 2005 May; 25(4):250-4. PubMed ID: 14963694
[TBL] [Abstract][Full Text] [Related]
6. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
Caramaschi P; Martinelli N; Volpe A; Pieropan S; Tinazzi I; Patuzzo G; Mahamid H; Bambara LM; Biasi D
Clin Rheumatol; 2009 Jul; 28(7):807-13. PubMed ID: 19301062
[TBL] [Abstract][Full Text] [Related]
7. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results.
Caramaschi P; Volpe A; Tinazzi I; Bambara LM; Carletto A; Biasi D
Rheumatol Int; 2006 Dec; 27(2):203-5. PubMed ID: 17006704
[TBL] [Abstract][Full Text] [Related]
8. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year.
Biasi D; Carletto A; Caramaschi P; Zeminian S; Pacor ML; Corrocher R; Bambara LM
Rev Rhum Engl Ed; 1998 Dec; 65(12):745-50. PubMed ID: 9923042
[TBL] [Abstract][Full Text] [Related]
9. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis.
Ceru S; Pancera P; Sansone S; Sfondrini G; Codella O; De Sandre G; Lechi A; Lunardi C
Clin Exp Rheumatol; 1997; 15(4):381-5. PubMed ID: 9272298
[TBL] [Abstract][Full Text] [Related]
10. A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.
Biasi D; Caramaschi P; Carletto A; Zeminian S; Schiavon F; Bambara LM
Clin Rheumatol; 1997 Jan; 16(1):111-2. PubMed ID: 9132317
[No Abstract] [Full Text] [Related]
11. [Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature].
Riemekasten G; Jepsen H; Burmester GR; Hiepe F
Z Rheumatol; 1998 Apr; 57(2):118-24. PubMed ID: 9627952
[TBL] [Abstract][Full Text] [Related]
12. Iloprost treatment summer-suspension: effects on skin thermal properties and cytokine profile in systemic sclerosis patients.
Auriemma M; Vianale G; Reale M; Costantini E; Di Nicola M; Romani GL; Merla A; Muraro R; Amerio P
G Ital Dermatol Venereol; 2013 Apr; 148(2):209-16. PubMed ID: 23588147
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
15. Iloprost infusion does not reduce oxidative stress in systemic sclerosis.
Volpe A; Biasi D; Caramaschi P; Bambara LM; Carletto A; Degan M; Minuz P
Rheumatol Int; 2008 Feb; 28(4):335-7. PubMed ID: 17704920
[TBL] [Abstract][Full Text] [Related]
16. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis.
Marczin N; Riedel B; Royston D; Yacoub M
Lancet; 1998 Aug; 352(9125):405-6. PubMed ID: 9717956
[No Abstract] [Full Text] [Related]
17. Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial.
Schioppo T; Orenti A; Boracchi P; De Lucia O; Murgo A; Ingegnoli F
Rheumatology (Oxford); 2018 Aug; 57(8):1408-1416. PubMed ID: 29733400
[TBL] [Abstract][Full Text] [Related]
18. [Iloprost therapy in systemic sclerosis].
Bali G; Aberer E
Hautarzt; 2003 Sep; 54(9):845-51. PubMed ID: 12955262
[TBL] [Abstract][Full Text] [Related]
19. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
20. [Iloprost for the treatment of systemic sclerosis].
Hachulla E; Launay D; Hatron PY
Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
